Technical Analysis for AMRN - Amarin Corporation plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.68% | |
| Fell Below 20 DMA | Bearish | 0.68% | |
| Bollinger Band Squeeze | Range Contraction | 0.68% | |
| BB Squeeze Started | Range Contraction | 0.68% | |
| Fell Below 50 DMA | Bearish | -4.00% | |
| Narrow Range Bar | Range Contraction | -4.00% | |
| Gapped Down | Weakness | -4.00% | |
| 200 DMA Resistance | Bearish | -6.41% | |
| Crossed Above 50 DMA | Bullish | -6.41% | |
| BB Squeeze Ended | Range Expansion | -6.41% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 1 hour ago |
| Down 1% | about 1 hour ago |
| Down 3% | 3 days ago |
| Possible NR7 | 3 days ago |
| 20 DMA Support | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/01/2024
Amarin Corporation plc Description
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases. Its product development program areas include lipid science and therapeutic benefits of polyunsaturated fatty acids. The company lead product comprises Vascepa, a prescription-only omega-3 fatty acid comprising icosapent ethyl as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It also engages in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Acid Organic Compounds Cardiovascular Disease Therapeutic Products Vascular Disease Lipid Nutrition Cholesterol Lipoprotein Fatty Acids Low Density Lipoprotein Triglyceride Hypertriglyceridemia Statin Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.485 |
| 52 Week Low | 0.651 |
| Average Volume | 1,197,965 |
| 200-Day Moving Average | 0.95 |
| 50-Day Moving Average | 0.91 |
| 20-Day Moving Average | 0.90 |
| 10-Day Moving Average | 0.91 |
| Average True Range | 0.06 |
| RSI (14) | 45.36 |
| ADX | 12.67 |
| +DI | 22.28 |
| -DI | 21.99 |
| Chandelier Exit (Long, 3 ATRs) | 0.85 |
| Chandelier Exit (Short, 3 ATRs) | 0.99 |
| Upper Bollinger Bands | 0.97 |
| Lower Bollinger Band | 0.82 |
| Percent B (%b) | 0.32 |
| BandWidth | 16.65 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.002 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.93 | ||||
| Resistance 3 (R3) | 0.94 | 0.93 | 0.92 | ||
| Resistance 2 (R2) | 0.93 | 0.91 | 0.92 | 0.92 | |
| Resistance 1 (R1) | 0.90 | 0.90 | 0.89 | 0.89 | 0.92 |
| Pivot Point | 0.88 | 0.88 | 0.88 | 0.88 | 0.88 |
| Support 1 (S1) | 0.86 | 0.87 | 0.85 | 0.85 | 0.82 |
| Support 2 (S2) | 0.84 | 0.86 | 0.84 | 0.82 | |
| Support 3 (S3) | 0.81 | 0.84 | 0.82 | ||
| Support 4 (S4) | 0.81 |
